📈 Cagrilintide Protocol

Educational purposes only — not medical advice.

Lesson 1: What Is Cagrilintide?

Cagrilintide, often shortened to Cagri, is a long-acting amylin analogue.

Amylin is a hormone involved in:

✅ Fullness signaling
✅ Slower stomach emptying
✅ Meal-size control
✅ Appetite regulation
✅ Metabolic research

Cagrilintide is different from GLP-1 compounds because it works mainly through amylin pathways, not GLP-1 receptors. It is also being studied with semaglutide in the combination known as CagriSema.

⸻

Lesson 2: Why Researchers Study It

Researchers study Cagrilintide because it may help support:

* Reduced food-seeking behavior
* Increased satiety
* Smaller meal size
* Body composition research
* GLP-1 combination research

In Phase 2 research, once-weekly cagrilintide showed dose-related effects on body weight, with the 2.4 mg group showing notable results by 26 weeks.

⸻

Lesson 3: Common Protocol

💧 The Once-Weekly Escalation Schedule The standard protocol for cagrilintide follows a strict 4-week escalation cycle via once-weekly subcutaneous injections to keep stomach upset to a minimum:

🏁 Weeks 1–4 (Initiation): Start low at 0.3 mg weekly to let the body adapt.
📈 Weeks 5–8 (Step-Up): Increase to 0.6 mg weekly.
🔄 Weeks 9–12 (Transition): Move up to 1.2 mg weekly.
🚀 Weeks 13–16 (Advanced): Step up to 2.4 mg weekly.
👑 Week 17+ (Peak Maintenance): Reach the final target dose of 4.5 mg weekly.

🤝 Combining with GLP-1s (The "CagriSema" Effect)

Does it affect the dose? Yes! 💥

Why? Cagrilintide is an amylin analogue (slowing the stomach and hitting brain satiety centers), while GLP-1s target a different pathway in the gut and hypothalamus. When combined, they create a massive synergistic effect—meaning they amplify each other's weight management and appetite-crushing power far more than when used alone.

Because this combo dramatically delays digestion, the dosing protocol changes in these ways:

⏱️ Synchronized Steps: Both peptides must start at their absolute lowest entry doses together and scale up at the exact same 4-week pace.
🛑 The Pause Button: If stomach distress or severe nausea kicks in, escalation for both compounds is paused. They are held at the current tier for an extra 2 to 4 weeks until the body adapts.

⸻

Lesson 4: When To Increase

Researchers may consider increasing only when:

✅ The current amount is tolerated
✅ Nausea or constipation is controlled
✅ Food noise or hunger is still significant
✅ Progress has slowed after several weeks
✅ Hydration, protein, and meal structure are consistent

A simple rule:

Do not increase just because the calendar says so. Increase only when the current amount is no longer doing enough and is well tolerated.

⸻

Lesson 5: When To Stop Increasing

Researchers may stop increasing when:

* Fullness is strong
* Food intake becomes too low
* Nausea increases
* Constipation becomes difficult
* Energy drops too much
* Progress continues at the current amount

With Cagri, more is not always better. The goal is the lowest effective amount, especially when combined with a GLP-1.

⸻

Lesson 6: Common Side Effects To Watch For

The most common side effects reported in Cagrilintide research are digestive-related.

Watch for:

* Nausea
* Constipation
* Diarrhea
* Vomiting
* Stomach discomfort
* Reduced appetite
* Fatigue
* Injection-site reactions

Published trials describe GI effects and administration-site reactions as the most frequent adverse events.

⸻

Lesson 7: Important Safety Notes

Cagrilintide is not the same as Tirzepatide, Semaglutide, or Retatrutide. It may stack strongly with GLP-1 compounds because both can reduce appetite and slow digestion.

Use extra caution in research involving:

* History of severe GI disease
* Gastroparesis
* Very low calorie intake
* Dehydration risk
* Gallbladder issues
* Combining multiple appetite-suppressing compounds
* Pregnancy or breastfeeding

Seek medical help for severe abdominal pain, persistent vomiting, fainting, severe dehydration, allergic reaction, or signs of bowel obstruction.

⸻